Bisphosphonate-Associated Osteonecrosis of the Jaw ; Humans

No abstract available.
Abscess ; Bisphosphonate-Associated Osteonecrosis of the Jaw

No abstract available.
Abscess* ; Bisphosphonate-Associated Osteonecrosis of the Jaw*

Bisphosphonates are widely used to treat osteoporosis, hypercalcemia of malignant tumor. Despite their clinical benefit, bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a newly documented complication to patients receiving these drugs and first recognized by Marx in 2003. Thus, consideration of prevention and needs regarding unequivocal treatment regimen have emerged. Recently, several authors emphasized reports on appropriate clinical availability of surgical approach. It serves to concern about guideline for surgical and conservative treatment modalities. So, it is the purpose of this paper to review the current literatures about treatment regimens of BRONJ.
Bisphosphonate-Associated Osteonecrosis of the Jaw ; Diphosphonates ; Humans ; Hypercalcemia ; Osteonecrosis ; Osteoporosis

Bisphosphonate-Associated Osteonecrosis of the Jaw ; complications ; Humans ; Periodontal Abscess ; complications

The prevalence of osteoporosis was increased. Bisphosphonates are effective medications for osteoporosis because these are increasing bone mineral density and lowering the risk of fractures. Recently, bisphosphonate associated osteonecrosis of the jaws has been well documented. Most reports relate to complications resulting from intravenous bisphosphonate therapy. Oral bisphosphonates have a good safety profile in the treatment of osteoprosis. A few cases were reported about oral bisphosphonates associated osteonecrosis, and we could not find Korean case in literatures. The aim of this repot is to present a Korean women case of osteonecrosis of the jaw associated with oral bisphosphonate treatment for osteoprosis.
Bisphosphonate-Associated Osteonecrosis of the Jaw ; Bone Density ; Diphosphonates ; Female ; Humans ; Jaw ; Osteonecrosis ; Osteoporosis ; Polymethacrylic Acids ; Prevalence

Bisphosphonates are compounds used to treat osteoporosis and malignant bone metastasis. Despite the benefits related to the use of these medications, osteonecrosis of the jaws is a significant complication in a subset of patients receiving these drugs. This complication occurs either spontaneously or after a simple dento-alveolar surgery. Recently there were two patients who showed the features of bisphosphonate related osteonecrosis of the jaws (BRONJ) in Gangneung-Wonju National University Dental Hospital. The patients revealed the clinical and radiological features of classical osteomyelitis. This report presents two cases of BRONJ which were examined by plain radiography and computed tomography.
Bisphosphonate-Associated Osteonecrosis of the Jaw ; Diphosphonates ; Humans ; Jaw ; Neoplasm Metastasis ; Osteomyelitis ; Osteonecrosis ; Osteoporosis ; Tomography, X-Ray Computed

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of Bisphosphonates (BPs) use. These days, oral bisphosphonates are normally prescribed to treat osteoporosis. Intravenous BPs are used extensively to treat osteolytic bone lesions related to multiplemyeloma and bone metastasis of solid cancers, breast cancer or prostate cancer. As the prescription of BPs is universalized and the number of people treated with BPs is increasing, an accurate understanding and proper management of BRONJ are required. The aim of this study was to improve the clinicians'understanding of BRONJ by reviewing the literature. To achieve this, this paper introduces case reports as well as the current concept of BRONJ based on the 2009 updates by American Association of Oral and Maxillofacial (AAOMS) including the definition, epidemiology, etiology, diagnosis, treatment and prevention of BRONJ.
Bisphosphonate-Associated Osteonecrosis of the Jaw ; Breast Neoplasms ; Diphosphonates ; Jaw Diseases ; Neoplasm Metastasis ; Osteonecrosis ; Osteoporosis ; Prescriptions ; Prostatic Neoplasms

Although pathophysiology, incidence, and factors associated with the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ) and management strategies for patients treated with bisphosphonates or patients with BRONJ are well-established, few guidelines or recommendations are available for patients with a history of successfully healed BRONJ. We present a case of successful dental implant treatment after healing of BRONJ in the same region of the jaw, and speculate that implant placement is possible after healing of BRONJ surgery in select cases.
Bisphosphonate-Associated Osteonecrosis of the Jaw* ; Dental Implants* ; Diphosphonates ; Humans ; Incidence ; Jaw ; Osteonecrosis ; Replantation

OBJECTIVES: Osteonecrosis of the jaw (ONJ) involving the use of bisphosphonates is referred to as bisphosphonate-associated ONJ (BONJ). Inflammation also can cause ONJ and it may be called inflammation-associated ONJ (IONJ). The aim of this study was to compare clinical characteristics between BONJ and IONJ. MATERIALS AND METHODS: Medical records at the Ajou University Hospital were reviewed using key words "osteonecrosis", "sequestrum", and "dead bone" of the mandible and maxilla. Eighteen patients diagnosed with ONJ were identified from January 2003 to December 2009. Using criteria from the American Association of Oral and Maxillofacial Surgeons, 12 cases were diagnosed as BONJ and six as IONJ. Clinical characteristics and treatment modalities, outcomes of two groups of patients were investigated. RESULTS: Patients of the BONJ group were older than those of IONJ group (median: 76.5 years vs. 60 years). In the BONJ group, mandible was more commonly involved sites and percentage of diabetic patients was higher. Three of 12 (25%) BONJ patients received oral glucocorticoids, while none of the IONJ patients. Ten (83.3%) of the BONJ cases and 2 (33.3%) of the IONJ cases were triggered by dental extractions. Though duration of ONJ treatment was longer in the BONJ group than the IONJ group (6.4+/-5.2 months vs. 2.9+/-1.9 months), both groups eventually showed good prognosis. CONCLUSIONS: ONJ may occur in the absence of bisphosphonate. BONJ occurred in older patients, and needed longer treatment duration compared to IONJ. Prognosis of ONJ was relatively good.
Bisphosphonate-Associated Osteonecrosis of the Jaw ; Diphosphonates ; Glucocorticoids ; Humans ; Inflammation ; Jaw ; Mandible ; Maxilla ; Medical Records ; Osteonecrosis ; Osteoporosis ; Prognosis